Yaqing Liu

University of South China — China

Medicine · Health Sciences

2h-index10citations26works0.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(18), Cancer Immunotherapy and Biomarkers(17), Immunotherapy and Immune Responses(5), Cancer Research and Treatments(3), Microgrid Control and Optimization(1)

Publications26 total

Sarcopenia as a predictor of negative health outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome·2025Open Access

Prevalence and risk factors of depression in middle-aged and elderly women with diabetes: a protocol of systematic review and meta-analysis

BMJ Open·2025Open Access

A Power Source-Grid Flexible Load Dispatch Method Under Carbon Emission Constraints

International Journal of High Speed Electronics and Systems·2025Open Access

Table S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Data from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

page 1 of 2Next →

Frequent Co-authors

Zhen Zhang(18), Xuan Zhao(18), Qitai Zhao(18), Xinfeng Chen(18), Congcong Li(18), Chunyi Shen(18), Lijie Song(18), Lijun Miao(18), Fuyou Guo(18), Jie Zhao(18), Weiyue Gu(18), Yi Zhang(18), Xiaoning Mou(17), Wenchao Li(2), Yiting Pan(2), Longhan Zhang(2), Lingqiao Song(2), Zeyuan Long(2), Xiaoning Mou(1), Dan Wang(1)